(Q33386427)

26 July 2017

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge (English)

1 reference

26 July 2017

1 reference

Joel R Haynes

1

1 reference

26 July 2017

Leslie Dokken

2

1 reference

26 July 2017

James A Wiley

3

1 reference

26 July 2017

Andrew G Cawthon

4

1 reference

26 July 2017

John Bigger

5

1 reference

26 July 2017

Allen G Harmsen

6

1 reference

26 July 2017

Charles Richardson

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

19 November 2008

1 reference

26 July 2017

1 reference

26 July 2017

27

1 reference

26 July 2017

4

1 reference

26 July 2017

530-541

1 reference

Influenza vaccine: the challenge of antigenic drift.

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Development of effective vaccines against pandemic influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Scientific barriers to developing vaccines against avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

H5N1 viruses and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

H5N1 influenza--continuing evolution and spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Influenza and the challenge for immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Avian influenza A (H5N1) in 10 patients in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Probable person-to-person transmission of avian influenza A (H5N1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

The development of live attenuated cold-adapted influenza virus vaccine for humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Live attenuated versus inactivated influenza vaccine in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Influenza virus matrix protein is the major driving force in virus budding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Production of Immunogenic HIV-1 Viruslike Particles in Stably Engineered Monkey Cell Lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Caveolin-1 interacts with the Gag precursor of murine leukaemia virus and modulates virus production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Palmitoylation of the Autographa californica multicapsid nucleopolyhedrovirus envelope glycoprotein GP64: mapping, functional studies, and lipid rafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Requirement for GP64 to drive efficient budding of Autographa californica multicapsid nucleopolyhedrovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

Baculovirus stimulates antiviral effects in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.11.011

1 reference

26 July 2017

1 reference